Pathogenesis and diagnosis of drug-induced thrombocytopenia

doi:10.19803/j.1672-8629.20240054

Abstract

Abstract: Drug-Induced Thrombocytopenia (DITP) is the most common secondary thrombocytopenia in clinical practice. Based on the pathogenic mechanism, thrombocytopenia can be divided into two major categories: non-immune-mediated and drug-induced immune thrombocytopenia (DIIT). The latter is again classified into four categories based on different immune-mediated mechanisms. In addition to the classical pathway of drug-induced immune thrombocytopenia caused by drug-dependent platelet-reactive antibodies (DDAbs) binding to platelets, other categories include heparin-induced thrombocytopenia (HIT) and immune checkpoint inhibitors-induced thrombocytopenia(ICI-ITP). With the intensified development of vaccines and mass vaccinations following the global COVID-19 pandemic, a newly emerged category within DITP is vaccine-induced thrombotic thrombocytopenia (VITT). This article, in conjunction with related literature published in recent years, reviews the pathogenic characteristics and diagnosis of the aforementioned types of DITP, sorts out databases related to DITP and predicts the prospects of research.

Key words: drug-induced thrombocytopenia(DITP), immune, drug-dependent, antibodies, heparin, vaccine, induced, adverse drug reactions

CLC Number:

R994.11
R978

NIE Xiaolu, MA Jingyao, SUN Feng, ZHAN Siyan. Pathogenesis and diagnosis of drug-induced thrombocytopenia[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 829-835.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240054

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I7/829

References

[1] BAKCHOUL T, MARINI I.Drug-associated thrombocytopenia[J]. Hematology Am Soc Hematol Educ Program, 2018(1): 576-583.
[2] VAN DEN BEMT PM, MEYBOOM RH, EGBERTS AC. Drug-induced immune thrombocytopenia[J]. Drug Safety, 2004, 27(15): 1243-1252.
[3] CURTIS BR.Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms[J]. Immunohematology, 2014, 30(2): 55-65.
[4] VISENTIN GP, LIU CY.Drug-induced thrombocytopenia[J]. Hematol Oncol Clin North Am, 2007, 21(4): 685-696.
[5] DHAKAL B, KREUZIGER LB, REIN L, et al.Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study[J]. Lancet Haematol, 2018, 5(5): e220-e231.
[6] HOGAN M, BERGER JS.Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management[J]. Vasc Med, 2020, 25(2): 160-173.
[7] ZHANG D, XU Y, WANG X, et al.Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2023, 79(10): 1303-1314.
[8] CAREY PJ.Drug-induced myelosuppression: diagnosis and management[J]. Drug Safety, 2003, 26(10): 691-706.
[9] TOWHID ST, TOLIOS A, MÜNZER P, et al. Stimulation of platelet apoptosis by balhimycin[J]. Biochemical and Biophysical Research Communications, 2013, 435(2): 323-326.
[10] LI YR, JIANG Y, WANG HX, et al.Safety-related drug withdrawals in china between 1999 and 2021: a systematic investigation and analysis[J]. Drug Safety, 2022, 45(7): 737-745.
[11] GAO A, ZHANG LL, ZHONG DS.Chemotherapy-induced thrombocytopenia:literature review[J]. Discov Oncol, 2023, 14(1): 10.
[12] STACK A, KHANAL R, DENLINGER C.Oxaliplatin-induced immune thrombocytopenia: a case report and literature review[J]. Clin Colorectal Cancer, 2021, 20(1): e1-e4.
[13] ABDERRAHIM N, TAMAM B, JOHANNA S, et al.Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura(ITP)[J]. European Journal of Haematology, 2012, 88(2): 167-174.
[14] PEERSCHKE EIB, BIREE A, WEI Y, et al.Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura[J]. British Journal of Haematology, 2010, 148(4): 638-645.
[15] KUO YJ, CHEN YR, HSU CC, et al.An αIIb β3 antagonist prevents thrombosis without causing Fc receptor γ-chain IIa-mediated thrombocytopenia[J]. J Thromb Haemost, 2017, 15(11): 2230-2244.
[16] VAYNE C, GUÉRY E, ROLLIN J, et al. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia[J]. Journal of Clinical Medicine, 2020, 9(7): 2212.
[17] MARINI I, UZUN G, JAMAL K, et al.Treatment of drug-induced immune thrombocytopenias[J]. Haematologica, 2022, 107(6): 1264-1277.
[18] GRUEL Y, DE MAISTRE E, POUPLARD C, et al.Diagnosis and management of heparin-induced thrombocytopenia[J]. Anaesthesia Critical Care & Pain Medicine, 2020, 39(2): 291-310.
[19] ROLLIN J, POUPLARD C, GRUEL Y.Risk factors for heparin-induced thrombocytopenia: focus on Fcγ receptors[J]. Thrombosis and Haemostasis, 2016, 116(11): 799-805.
[20] AREPALLY GM.Clinical practice. Heparin-induced thrombocytopenia[J]. N Engl J Med, 2006, 355: 809-817.
[21] GREINACHER A, SELLENG K, WARKENTIN TE.Autoimmune heparin-induced thrombocytopenia[J]. Journal of Thrombosis and Haemostasis, 2017, 15(11): 2099-2114.
[22] KASTHURI RS, GLOVER SL, JONAS W, et al.PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI[J]. Blood, 2012, 119(22): 5285-5293.
[23] PERDOMO J, LEUNG HHL, AHMADI Z, et al.Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia[J]. Nature Communications, 2019, 10(1): 1322.
[24] XIAO ZH, VISENTIN GP, DAYANANDA KM, et al.Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion[J]. Blood, 2008, 112(4): 1091-1100.
[25] WARKENTIN TE.High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review[J]. Expert Review of Hematology, 2019, 12(8): 685-698.
[26] WARKENTIN TE, ROBERTS RS, HIRSH J, et al.An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients[J]. Archives of Internal Medicine, 2003, 163(20): 2518-2524.
[27] KLOK FA, PAI M, HUISMAN MV, et al.Vaccine-induced immune thrombotic thrombocytopenia[J]. The Lancet Haematology, 2022, 9(1): e73-e80.
[28] PAVORD S, SCULLY M, HUNT BJ, et al.Clinical features of vaccine-induced immune thrombocytopenia and thrombosis[J]. New England Journal of Medicine, 2021, 385(18): 1680-1689.
[29] SCHULTZ NH, SØRVOLL IH, MICHELSEN AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination[J]. New England Journal of Medicine, 2021, 384(22): 2124-2130.
[30] SEE I, SU JR, LALE A, et al.US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021[J]. JAMA, 2021, 325(24): 2448-2456.
[31] ALTHAUS K, MÖLLER P, UZUN G, et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia[J]. Haematologica, 2021, 106(8): 2170.
[32] GREINACHER A, SELLENG K, PALANKAR R, et al.Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia[J]. Blood, 2021, 138(22): 2256-2268.
[33] VAN DE MUNCKHOF A, KRZYWICKA K, AGUIAR SD, et al. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination[J]. European Journal of Neurology, 2022, 29(1): 339-344.
[34] BAGCHI S, YUAN R, ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annual Review of Pathology: Mechanisms of Disease, 2021, 16: 223-249.
[35] CASAGRANDE S, SOPETTO GB, BERTALOT G, et al.Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations[J]. Cancers(Basel), 2024, 16(7): 1440.
[36] HADDAD TC, ZHAO SZ, LI MJ, et al.Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival[J]. Cancer Immunology, Immunotherapy, 2022, 71(5): 1157-1165.
[37] CALVO R.Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia[J]. Frontiers in Pharmacology, 2019, 10: 454.
[38] HADFIELD MJ, MUI G.A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanoma[J]. Journal of Oncology Pharmacy Practice, 2020, 26(6): 1530-1532.
[39] WILLIAMSON DR, ALBERT M, HEELS-ANSDELL D, et al.Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes[J]. Chest, 2013, 144(4): 1207-1215.
[40] Consensus expert Group on Emergency Management of adult thrombocytopenia in China. Expert consensus on emergency management of adult thrombocytopenia in China[J]. Chin J Emerg Med(中华急诊医学杂志), 2022, 3(2): 161-168.
[41] The Society of Chemotherapy, China Anti-Cancer Association, Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association. Consensus on the clinical diagnosis, treatment, and prevention of chemotherapy-induced thrombocytopenia in China (2019 version)[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(18): 923-929.
[42] Working Group of Chinese Guideline for the Diagnosis and Treatment of Childhood Primary Immune Thrombocytopenia, the Subspecialty Group of Hematologic Diseases, the Society of Pediatrics, Chinese Medical Association, the Editorial Board, Chinese Journal of Pediatrics. Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021)[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2021, 59(10): 810-819.
[43] ARNOLD DM, CURTIS BR, BAKCHOUL T.Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH[J]. Journal of Thrombosis and Haemostasis, 2015, 13(4): 676-678.
[44] ARNOLD DM, KUKASWADIA S, NAZI I, et al.A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia[J]. Journal of Thrombosis and Haemostasis, 2013, 11(1): 169-176.
[45] LO GK, JUHL D, WARKENTIN TE, et al.Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings[J]. Journal of Thrombosis and Haemostasis, 2006, 4(4): 759-765.
[46] MEN JL, REN J.Progress in laboratory diagnosis of heparin induced thrombocytopenia[J]. Chin J Lab Med(中华检验医学杂志), 2016, 39: 795-800.
[47] NAZY I, SACHS UJ, ARNOLD DM, et al.Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC subcommittee on platelet immunology[J]. Journal of Thrombosis and Haemostasis, 2021, 19(6): 1585-1588.
[48] SACHS UJ, COOPER N, CZWALINNA A, et al.PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison[J]. Thrombosis and Haemostasis, 2021, 121(12): 1622-1627.
[49] MITTA A, CURTIS BR, REESE JA, et al.Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data[J]. Am J Hematol, 2019, 94(3): E76-E78.
[50] GEORGE JN, ASTER RH.Drug-induced thrombocytopenia: pathogenesis, evaluation, and management[J]. Hematology Am Soc Hematol Educ Program, 2009(1): 153-158.
[51] GEORGE JN, RASKOB GE, SHAH SR, et al.Drug-induced thrombocytopenia: a systematic review of published case reports[J]. Ann Intern Med, 1998, 129(11): 886-890.
[52] GEORGE JN.Drug-Induced Thrombocytopenia[EB/OL]. [2024-01-24].https://ouhsc.edu/platelets/ditp.html.
[53] KUHN M, LETUNIC I, JENSEN LJ, et al.The SIDER database of drugs and side effects[J]. Nucleic Acids Res, 2016, 44(D1): D1075-D1079.
[54] TATONETTI NP, YE PP, DANESHJOU R, et al.Data-driven prediction of drug effects and interactions[J]. Sci Transl Med, 2012, 4(125): 125-131.
[55] KAPLOWITZ N.Idiosyncratic drug hepatotoxicity[J]. Nat Rev Drug Discov, 2005, 4(6): 489-499.
[56] WALLER PC.Measuring the frequency of adverse drug reactions[J]. Br J Clin Pharmacol, 1992, 33(3): 249-252.